Trials still taking part

3,479 trials in OnCo have a registry record saying they are still taking part, 2,883 of them recruiting now, across 72,747 recruiting sites in 79 countries. Filter by cancer, by country, by phase and by who the registry says the trial is open to.

Read from ClinicalTrials.gov on 2026-10-08. A status describes the whole trial on that date, not a particular hospital: a site near you can be closed while the trial recruits elsewhere, and a trial can close between that date and today. The age and sex rules are the only eligibility the registry states in a field; everything else, including prior treatment, biomarkers and organ function, is in the criteria text on the registry record each row links to. Nothing here decides whether you can join. Take it to your team, or ask the study contact named on the registry record.

3,479 trial

Trial
CIRCULATE-US NCT05174169	Recruiting	Colorectal cancer	Phase 2/3	18 and over	Canada, Puerto Rico, United States	964
Lung-MAP (SWOG S1400 and S1900) NCT03851445	Recruiting	Non-small-cell lung cancer, Lung cancer (all types)	Platform trial	18 and over	United States	950
SCARLET (SWOG S2212) NCT05929768	Recruiting	Triple-negative breast cancer (TNBC)	Phase 3	18 and over	Mexico, Puerto Rico, United States	923
OptimICE-pCR (A012103) NCT05812807	Recruiting	Triple-negative breast cancer (TNBC)	Phase 3	18 and over	Canada, Puerto Rico, United States	797
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Ch NCT04267848	Recruiting	Resectable stage I to III non-small-cell lung cancer	Phase 3	18 and over	Guam, United States	616
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence NCT06492616	Recruiting	Metastatic cancer (cancer that has spread)	Phase 3	18 and over	Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hong Kong, Hungary, Italy, Malaysia, Netherlands, Poland, Portugal, Romania, Singapore, South Korea, Spain, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States	501
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Recruiting	Metastatic cancer (cancer that has spread)	Phase 3	18 and over	Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Costa Rica, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, United States, Vietnam	500
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT07222566	Recruiting	Non-small-cell lung cancer	Phase 3	18 and over	Argentina, Australia, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Poland, Puerto Rico, Spain, Taiwan, Turkey (Türkiye), United States	454
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer NCT05624996	Recruiting	Unresectable stage III non-small-cell lung cancer	Phase 3	18 and over	Canada, United States	446
AGCT1531 NCT03067181	Recruiting	Germ cell tumours of childhood and adolescence (extracranial and CNS), Extragonadal germ cell tumour, Testicular germ cell tumours, Childhood cancers (all types)	Phase 3	18 and over	Australia, Canada, India, Japan, New Zealand, Puerto Rico, Saudi Arabia, United Kingdom, United States	438
ComboMATCH (EAY191) NCT05564377	Recruiting	Rare cancers	Platform trial	18 and over	Puerto Rico, United States	430
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) NCT07144280	Recruiting	Non-small-cell lung cancer	Phase 3	18 and over	Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Finland, France, Germany, Greece, India, Israel, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States	423
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer NCT06119581	Recruiting	Non-small-cell lung cancer, KRAS G12C-mutant non-small-cell lung cancer	Phase 3	18 and over	Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Greece, Hungary, India, Italy, Japan, Mexico, Netherlands, Norway, Poland, Portugal, Romania, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States	414
Alliance A071401 NCT02523014	Recruiting	Meningioma	Phase 2	18 and over	United States	413
AHOD2131 (COG / NCTN) NCT05675410	Recruiting	Hodgkin lymphoma, Early-stage classical Hodgkin lymphoma (stage I to II)	Phase 3	Under 18, 18 and over	Canada, Puerto Rico, United States	398
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors NCT07018869	Recruiting	Rectal cancer, Colon cancer (adenocarcinoma of the colon)	Phase 3	18 and over	Guam, Puerto Rico, United States	383
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemoth NCT06616584	Recruiting	Non-small-cell lung cancer	Phase 2/3	18 and over	United States	379
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G NCT04613596	Recruiting	Non-small-cell lung cancer, Small-cell lung cancer, KRAS G12C-mutant non-small-cell lung cancer	Phase 2/3	18 and over	Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Norway, Peru, Philippines, Poland, Portugal, Romania, Serbia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, United States	378
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer NCT06712316	Recruiting	Non-small-cell lung cancer, Small-cell lung cancer	Phase 2/3	18 and over	Argentina, Australia, Belgium, Brazil, Bulgaria, Chile, China, France, Georgia, Germany, Hungary, Italy, Japan, Poland, Romania, South Korea, Spain, Switzerland, Thailand, Turkey (Türkiye), United Kingdom, United States	363
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu NCT06758401	Recruiting	Non-small-cell lung cancer, Small-cell lung cancer, PD-L1-high non-small-cell lung cancer without a driver mutation	Phase 3	18 and over	Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, Poland, Romania, Saudi Arabia, Slovakia, South Korea, Spain, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States	355
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer NCT06890598	Recruiting	Non-small-cell lung cancer, KRAS G12C-mutant non-small-cell lung cancer	Phase 3	18 and over	Australia, Austria, Belgium, Brazil, Chile, China, Czechia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States	345
myeloMATCH NCT05564390	Recruiting	Acute myeloid leukaemia	Platform trial	18 and over	Canada, Puerto Rico, United States	341
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer NCT07222800	Recruiting	Colorectal cancer	Phase 3	18 and over	Argentina, Australia, Belgium, Brazil, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Poland, Puerto Rico, Spain, Taiwan, United States	332
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer NCT06958328	Recruiting	Locally advanced unresectable pancreatic ductal adenocarcinoma	Phase 3	18 and over	Canada, United States	327
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi NCT05920356	Recruiting	Non-small-cell lung cancer, Small-cell lung cancer, KRAS G12C-mutant non-small-cell lung cancer	Phase 3	18 and over	Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hong Kong, Hungary, Italy, Japan, Latvia, Malaysia, Mexico, Netherlands, Peru, Poland, Portugal, Puerto Rico, Romania, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, United States	324
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700	Recruiting	Triple-negative breast cancer (TNBC), Early triple-negative breast cancer	Phase 3	18 and over	Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Israel, Italy, Japan, Malaysia, New Zealand, Norway, Peru, Philippines, Poland, Portugal, Romania, Singapore, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, United States, Vietnam	323
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer NCT04181060	Recruiting	EGFR-mutated non-small-cell lung cancer	Phase 3	18 and over	United States	320
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) NCT06393374	Recruiting	Triple-negative breast cancer (TNBC), Early triple-negative breast cancer	Phase 3	18 and over	Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Norway, Poland, Portugal, Singapore, South Korea, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom, United States	300
MOUNTAINEER NCT05253651	Recruiting	Colorectal cancer, HER2-amplified colorectal cancer	Phase 2	18 and over	Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, France, Germany, Greece, Ireland, Italy, Japan, Netherlands, Norway, Poland, Portugal, Slovakia, South Korea, Spain, Switzerland, Taiwan, United Kingdom, United States	298
MOUNTAINEER-03 NCT05253651	Recruiting	Colorectal cancer, HER2-amplified colorectal cancer	Phase 3	18 and over	Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, France, Germany, Greece, Ireland, Italy, Japan, Netherlands, Norway, Poland, Portugal, Slovakia, South Korea, Spain, Switzerland, Taiwan, United Kingdom, United States	298

(showing the first 30)

ClinicalTrials.gov data courtesy of the US National Library of Medicine. Trials with no registry identifier, and those the registry records as completed or closed, are in the full trials table.